EUVIMEDEUVIMED entdecken
Klinische Studie

Clinical and Analytical Evaluation of the Abbott Alinity m HR HPV Assay in a New Generation First‐Void Urine Collector

Severien Van Keer iD, Laura Téblick iD, Gilbert Donders, Steven Weyers, Jean Doyen, Ann Cornelis, Koen Van de Vijver, Katty Delbecque, Annemie De Smet, Pierre Van Damme, Alex Vorsters

Journal of Medical Virology · 2025-02 · 97 (2)

DOI: 10.1002/jmv.70254 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Medical Virology, online erschienen am 21.02.2025. Verfasst von Severien Van Keer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for the Evaluation of Vaccination (CEV), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Edegem, Belgium. Hauptthemen laut MEDLINE: Molecular Diagnostic Techniques, Papillomaviridae, Papillomavirus Infections, Urine. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Part of this work was supported by an Eurostars R&D-performing SME Grant CASUS (12396), co-funded by Eureka member countries and the European Union Horizon 202….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urine‐based self‐sampling approaches can simplify cervical screening programs whilst increasing response. This study reports on the performance of Abbott Alinity m HR HPV on urine, self‐collected at home using a new generation first‐void urination device that is suitable for postal delivery (Novosanis Colli‐Pee Small Volumes). First‐void urine and paired cervical samples from 297 females attending colposcopy (age 25–65, NCT04530201) were analysed for the presence of Human Papillomavirus (HPV) DNA. Cervical disease was confirmed by colposcopy and/or histology. HPV testing on first‐void urine was less sensitive for high‐grade cervical intraepithelial neoplasia (CIN2 +; ratio 0.91; 95% CI: 0.83–0.99), though equally specific (< CIN2; ratio 1.04; 95% CI: 0.92–1.19) compared to cervical samples at the manufacturer established cut‐off for cervical samples. Adjusting the cut‐off for first‐void urine improved sensitivity for CIN2+ (ratio 0.96; 95% CI: 0.90–1.03), whilst maintaining equal specificity compared to cervical samples (ratio 1.00; 95% CI: 0.88–1.14). Cohen's kappa agreements of HPV outcomes between sample pairs were good to excellent at both cut‐offs (range: 0.64–0.85). Using the HPV test's adjusted cutoff for first‐void urine, no difference in clinical sensitivity or specificity was observed between first‐void urine and cervical samples. These data highlight the importance of evaluating self‐sample‐specific cut‐offs for HPV assays, previously validated on cervical samples.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Diagnostic TechniquesPapillomaviridaePapillomavirus InfectionsUrineUrine Specimen CollectionUterine Cervical DysplasiaUterine Cervical NeoplasmsAdultAgedFemaleHumansMiddle AgedCervix UteriColposcopyDNA, ViralEarly Detection of CancerSensitivity and SpecificitySpecimen Handling

Stichwörter der Autor:innen

HPVcervical cancerclinical validationdiagnostic test accuracyfirst‐void urineself‐sampling

Substanzen

DNA, Viral

Autor:innen und Institutionen

  • Centre for the Evaluation of Vaccination (CEV), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Edegem, Belgium.
  • Department of Obstetrics and Gynaecology, General Regional Hospital Heilig Hart, Tienen, Belgium.
  • Femicare vzw, Clinical Research for Women, Tienen, Belgium.
  • Department of Obstetrics and Gynaecology, Antwerp University Hospital (UZA), Edegem, Belgium.
  • Department of Obstetrics and Gynecology, Ghent University Hospital, Ghent, Belgium.
  • Department Gynaecology-Obstetrics, University Hospital Liège, Liège, Belgium.

ORCID-Profile: Severien Van Keer, Laura Téblick

Förderung

  • Part of this work was supported by an Eurostars R&D-performing SME Grant CASUS (12396), co-funded by Eureka member countries and the European Union Horizon 202…

Zitieren

APA

Van Keer, S., Téblick, L., Donders, G., Weyers, S., Doyen, J., Cornelis, A., Van de Vijver, K., Delbecque, K., De Smet, A., Van Damme, P., & Vorsters, A. (2025). Clinical and Analytical Evaluation of the Abbott Alinity m HR HPV Assay in a New Generation First‐Void Urine Collector. Journal of Medical Virology, 97(2). https://doi.org/10.1002/jmv.70254

Vancouver

Van Keer S, Téblick L, Donders G, Weyers S, Doyen J, Cornelis A, et al. Clinical and Analytical Evaluation of the Abbott Alinity m HR HPV Assay in a New Generation First‐Void Urine Collector. Journal of Medical Virology. 2025;97(2). doi:10.1002/jmv.70254

BibTeX
@article{VanKeer2025,
  author = {Van Keer, Severien and Téblick, Laura and Donders, Gilbert and Weyers, Steven and Doyen, Jean and Cornelis, Ann and Van de Vijver, Koen and Delbecque, Katty and De Smet, Annemie and Van Damme, Pierre and Vorsters, Alex},
  title = {Clinical and Analytical Evaluation of the Abbott Alinity m HR HPV Assay in a New Generation First‐Void Urine Collector},
  journal = {Journal of Medical Virology},
  year = {2025},
  volume = {97},
  number = {2},
  doi = {10.1002/jmv.70254}
}
Kostenlos starten →